Rhythm Pharmaceuticals, Inc.(NASDAQ : RYTM)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.87%||69.82||1.0%||$467.59m|
|REGN||Regeneron Pharmaceuticals, Inc.||2.33%||625.48||2.7%||$405.42m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.25%||231.65||1.9%||$335.05m|
|SNSS||Sunesis Pharmaceuticals, Inc.||0.33%||3.01||0.7%||$210.41m|
|EXAS||EXACT Sciences Corp.||0.97%||78.17||17.9%||$155.65m|
|ARNA||Arena Pharmaceuticals, Inc.||-0.21%||91.79||13.7%||$145.12m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.73%||140.20||8.2%||$140.13m|
|BMRN||BioMarin Pharmaceutical, Inc.||1.07%||87.64||4.2%||$107.34m|
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.